Background/Aims: Natural compounds are a promising resource for anti-tumor drugs.
Introduction
leading cause of cancer-related death among males worldwide [1] . Although androgen deprivation therapy can control the progression of advanced PCa during the initial phase, nearly all patients eventually develop lethal metastatic castration-resistant prostate cancer. Therefore, the development of novel agents with an explicit mechanism for advanced PCa is vital and urgently needed.
various fruits and vegetables, are effective in cancer chemoprevention and chemotherapy and epidemiological research has shown that myricetin consumption is associated with a studies have further indicated that myricetin exerts multiple promising anti-tumor functions in various cancers, including anti-proliferative, pro-apoptotic, and anti-metastatic activities unclear.
proliferation and metastasis [18, 21] . Cell-free crystallographic and comparative molecular 50 in vitro and in vivo experiments, we found that myricetin exerted insights into the role of myricetin as a potential chemopreventive and therapeutic agent CXCR4 expression levels. China) was tested using the Transwell assay (without the Matrigel-coated membrane).
Materials and Methods

Clinical
RNA extraction and quantitative real-time PCR
3'; reverse, 5'-AGT TTG GAA GAG GCA GAGA-3'); E-cadherin (forward, 5'-GCC CCA TCA GGC CTC CGT TT-3';
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IHC analysis
and eosin were used according to the manufacturers' protocols. After the stained sections were mounted demonstrate that myricetin has selective cytotoxic and apoptosis-promoting effects in PCa cells.
Myricetin inhibits migration, invasion, and the epithelial-mesenchymal transition in PCa cells
Myricetin suppresses metastasis in many cancers [12, 13] . To determine the effects of myricetin on migration and invasion in PCa cells, we performed wound-healing and Transwell (with or without a Matrigel-coated membrane) assays in PC3 and DU145 cells the migration and invasion of PCa cells. progression and metastasis [25] . To determine the effect of myricetin on the EMT in PCa myricetin treatment. These results revealed a dose-dependent effect of myricetin treatment and demonstrate that myricetin inhibits migration, invasion, and the EMT in PCa cells. 
Myricetin inhibits PCa growth and the EMT in mouse models
Considering the anti-tumor effects of myricetin on PCa cells in vitro, we further investigated the inhibitory effects of myricetin on growth and the EMT in vivo by establishing a PC3 subcutaneous xenograft model in nude mice. The photographs and growth curves of models.
Myricetin inhibits PCa lung and bone metastasis in mouse models
To further investigate the anti-metastasis effects of myricetin on PCa cells in vivo, we inoculated PC3-luc-mCfp cells into the tail vein and tibial medullary cavity of nude mice to 4B). The number of CTCs was much lower in the myricetin group than in the vehicle group. We also used qRT-PCR to investigate the levels of human long interspersed nuclear element inhibits PCa metastasis in mouse models. has been found in many cancers, including hematopoietic malignancies and PCa, and is
Previous studies have shown that myricetin exhibits potent anti-cancer properties. Myricetin inhibits proliferation and promotes apoptosis in many types of cancer, such as also found that myricetin showed selective cytotoxic and apoptosis-promoting effects in PCa cells (PC3, DU145, and C4-2) in vitro results further showed that apoptosis-associated proteins were upregulated, whereas the in vivo results consistently showed that myricetin effectively suppressed the growth of subcutaneous our data show that myricetin has a slight inhibitory effect on CXCL12-induced migration patients. Therefore, these results further demonstrate that myricetin might be more suitable treatment of PCa. Meanwhile, we also need to further pharmacologically modify myricetin to improve its clinical availability and selectivity in future studies.
